Abiogen Pharma's New Cell Therapy Starts A Clinical Phase I-II In Peritoneal Carcinosis
10/19/2005 5:13:04 PM
PISA, Italy--(BUSINESS WIRE)--April 18, 2005--Abiogen Pharma today announced the start of a Phase I-II clinical trial in Italy using ABIO 05/01 cells for the treatment of peritoneal carcinosis.
The Phase I-II trial on peritoneal cancer patients will be conducted at the Oncology-Haematology Department of the University of Modena. The study will enrol approximately 18 patients with advanced tumors who have not responded to existing therapies. The purpose of the Phase I-II study is to evaluate ABIO 05/01's safety in humans and to establish safe dose ranges for further studies.
ABIO 05/01 is a cytotoxic cell line derived from the cells of a child with a rare form of T-cell leukaemia by Daniela Santoli, Ph.D., a professor at The Wistar Institute in Philadelphia. In vitro and in vivo, ABIO 05/01 cells have successfully caused the regression and disappearance of certain tumors without affecting normal tissue or producing side effects.
comments powered by